Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AVEO Pharmaceuticals, Inc. |
---|---|
Information provided by: | AVEO Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00660153 |
The FOLFOX6 regimen is a standard chemotherapy regimen for the treatment of patients with colorectal cancer and other gastrointestinal cancers. AV-951 is a targeted anti-angiogenesis agent that has demonstrated acceptable tolerability in a phase I clinical trial. This study is designed to test the hypothesis that AV-951 can be combined with standard FOLFOX6 chemotherapy for the treatment of patients with colorectal and other gastrointestinal cancers. The purpose of this study is to determine the maximum dose of AV-951 that can be safely combined with FOLFOX6 chemotherapy, and to evaluate the safety profile, tolerability, and pharmacokinetics of this combination.
Condition | Intervention | Phase |
---|---|---|
Colorectal Cancer Gastrointestinal Cancer |
Drug: AV-951 plus FOLFOX6 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment |
Official Title: | A Phase 1b, Open-Label, Dose-Escalation Study of AV-951 Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers |
Estimated Enrollment: | 30 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
single arm; multiple cohort: Experimental
Single arm; multiple cohort
|
Drug: AV-951 plus FOLFOX6
Investigational product, dosage and mode of administration (1 cycle = 4 weeks of treatment): AV-951: 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of AV-951 for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive AV-951 once daily for 3 weeks followed by 1 week off. AV-951 dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both AV-951 and the FOLFOX6 chemotherapy regimen are co-administered, AV-951 will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen. Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15. |
This is a Phase 1b, open-label, study design that will examine safety, tolerability, and maximum tolerated dose of AV-951 and FOLFOX6 in advanced colorectal cancer and other gastrointestinal cancers. In the study, only the doses of AV-951 will be escalated from 0.5 mg/day to 1.5 mg/day. All subjects will receive standard doses of FOLFOX6 chemotherapy every 2 weeks.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
At least 3 weeks since prior treatment with:
Exclusion Criteria:
Any of the following hematologic abnormalities:
Any of the following serum chemistry abnormalities:
Significant cardiovascular disease, including:
Prior radiotherapy:
Contact: Ferry Eskens, MD, PhD | +31 (10) 463-4897 | |
Contact: Elisabeth de Vries, MD | +31 (50) 361 28 21 |
Netherlands | |
Erasmus Medical Center; Department of Medical Oncology | Recruiting |
Rotterdam, Netherlands | |
Contact: Ferry Eskens, MD, PhD +31 (10) 463-4897 | |
Principal Investigator: Ferry Eskens, MD, PhD | |
University Medical Center Groningen; Internal Medicine, Department of Medical Oncology | Recruiting |
Groningen, Netherlands | |
Contact: Elisabeth de Vries, MD +31 (50) 361 28 21 | |
Principal Investigator: Elisabeth de Vries, MD |
Principal Investigator: | Ferry Eskens, MD, PhD | Erasmus Medical Center; Department of Medical Oncology |
Responsible Party: | AVEO Pharmaceuticals, Inc. ( Margaret Taleff Senior Director, Regulatory Affairs ) |
Study ID Numbers: | AV-951-103 |
Study First Received: | April 15, 2008 |
Last Updated: | February 25, 2009 |
ClinicalTrials.gov Identifier: | NCT00660153 History of Changes |
Health Authority: | United States: Food and Drug Administration; Netherlands: Medicines Evaluation Board (MEB) |
Advanced Colorectal Cancer and Other Gastrointestinal Cancers |
Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Colonic Diseases Gastrointestinal Neoplasms |
Intestinal Diseases Rectal Diseases Intestinal Neoplasms Colorectal Neoplasms |
Neoplasms Digestive System Diseases Neoplasms by Site Digestive System Neoplasms Gastrointestinal Diseases Colonic Diseases |
Gastrointestinal Neoplasms Intestinal Diseases Rectal Diseases Intestinal Neoplasms Colorectal Neoplasms |